Nasdaq:US$19.04 (+0.63) | HKEX:HK$30.35 (+1.05) | AIM:£3.04 (+0.08)
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2008-02-29

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate